Washington
+919359902383
+919359902383

Braunamide 10mg Price Bulk US Pharmaceutical Importer | Ernest Impex

Braunamide 10mg Capsule: High-Efficacy Immunomodulatory Therapy for Multiple Myeloma and Hematological Malignancies


Are you seeking a regulatory-compliant, high-volume Braunamide 10mg Capsule exporter from India? Ernest Impex, operating as the international trade arm of the Group of Ernest Pharmaceutical Pvt. Ltd., stands as a top-tier global supply partner, bulk wholesaler, and institutional drop-shipping specialist for advanced oncology therapies, cytostatic compounds, and specialized hematological medications. We coordinate secure, validation-ready cold-chain and standard shipping routes to safely deliver bulk cargo directly to licensed oncology centers, hospital pharmacy networks, and clinical distributors in Washington (USA), London (UK), Bangkok (Thailand), Canberra (Australia), Singapore, and Kingston (Jamaica).




Extensive Product Profile: In-Depth Insights on Braunamide 10mg Capsules


Braunamide 10mg Capsule, manufactured under strict global standards by Samarth Life Sciences Pvt. Ltd. (Oncology Division), is an advanced oral cytostatic formulation. Each capsule contains Lenalidomide ($10\text{ mg}$) as its active pharmaceutical ingredient. Structurally related to thalidomide, Lenalidomide is classified as an immunomodulatory drug (IMiD). It exhibits exceptional dual properties—acting both as a direct tumor-cell destructive agent and an immune-system modifier—making it a vital treatment path in contemporary hemato-oncology.


1. Clinical Indications & Target Therapeutic Applications

Braunamide 10mg Capsules are utilized within global oncological networks to manage:

  • Multiple Myeloma (MM): Indicated as a frontline maintenance therapy post-hematopoietic stem cell transplantation, or in combination with dexamethasone for individuals with relapsed or refractory plasma cell malignancies.

  • Myelodysplastic Syndromes (MDS): Prescribed to manage transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a specific genetic deletion 5q cytogenetic abnormality.

  • Mantle Cell Lymphoma (MCL): Indicated for the treatment of adult patients with relapsed or progressive MCL, an aggressive subtype of non-Hodgkin's lymphoma, following prior systemic regimens.

  • Follicular Lymphoma (FL): Administered in combination with targeted monoclonal antibodies (like rituximab) for patients with previously treated low-grade lymphatic system malignancies.

2. Comprehensive Mechanism of Action (MOA)


Lenalidomide targets malignant cells through multiple complex biological pathways to halt cancer progression and alter the cellular microenvironment:

  • E3 Ubiquitin Ligase Complex Binding: Lenalidomide binds directly to Cereblon (CRBN), a component of the cullin-RING E3 ubiquitin ligase enzyme complex. This binding alters the substrate specificity of the ligase, causing the selective ubiquitination and rapid degradation of two essential B-cell transcription factors: Ikaros (IKZF1) and Aiolos (IKZF3). The loss of these factors down-regulates key oncogenic drivers, halting the development of abnormal plasma cells.

  • Apoptosis Induction and G1 Growth Arrest: It stops the proliferation of cancer cells by forcing cell-cycle arrest in the G1 phase and inducing programmed cell death (apoptosis) directly within malignant cell colonies.

  • Angiogenesis Inhibition: It cuts off the tumor's nutrient supply lines by reducing the secretion of crucial angiogenic signaling factors, specifically Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF), effectively stopping the growth of new blood vessels inside bone marrow tumors.

  • Immune System Augmentation: It suppresses inflammatory cytokines (such as tumor necrosis factor-alpha [TNF-$\alpha$] and Interleukin-6 [IL-6]) while stimulating T-cell and Natural Killer (NK) cell activation. This boosts the patient's own immune system, allowing it to naturally target and destroy residual cancer cells.

3. Storage, Stability, and Handling Protocols

  • Temperature Matrix: Store Braunamide 10mg Capsules safely at controlled room temperature, strictly between 15°C to 30°C (59°F to 86°F) or in a cool, dry environment below 30°C. Protect the blister strips from excessive humidity, moisture, and direct thermal energy. Keep the product stored carefully within its original outer box package to protect the active structures from light degradation.

  • Capsule Integrity & Handling: Capsules must be swallowed whole with a full glass of water, either with or without food, at the same time each day. Do not break, chew, crush, or open the capsules. Healthcare providers and caregivers who are pregnant or planning to become pregnant must never handle open or damaged capsules due to severe risk of transdermal drug absorption.


Potential Side Effects of Braunamide 10mg


Given its potent mechanism as a systemic antineoplastic agent, patients taking Braunamide must undergo routine clinical monitoring to manage potential side effects.

  • Hematological Toxicity (Severe Bone Marrow Suppression): Profound neutropenia (dangerously low white blood cell counts increasing susceptibility to severe infections), thrombocytopenia (low platelet counts causing bleeding gums, nosebleeds, or bruising), and anemia (resulting in extreme tiredness and shortness of breath).

  • Thromboembolic Events (Boxed Warning Risk): Significantly increased risk of developing Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), myocardial infarction (heart attack), or stroke. Prophylactic antiplatelet or anticoagulant therapy is routinely prescribed concurrently.

  • Gastrointestinal Distress: Chronic diarrhea, severe constipation, nausea, loss of appetite, and abdominal discomfort.

  • Dermatological Manifestations: Pruritus (severe itching), generalized skin rashes, dry skin, and exfoliation.

  • Severe Systemic Alerts: Risk of hepatotoxicity (liver failure), severe tumor lysis syndrome (TLS), and peripheral neuropathy (tingling or numbness in the hands or feet).



PRESCRIPTION MEDICINE IS YES


Disclaimer: This structural product review is prepared strictly for international business-to-business (B2B) trade procurement, wholesale distribution networks, and digital optimization indexing. Braunamide (Lenalidomide) is a highly restricted, high-potency prescription cytostatic medication. It possesses strong teratogenic properties similar to thalidomide and can cause severe, life-threatening human birth defects. It must be prescribed and dispensed exclusively through registered risk evaluation and mitigation strategy (REMS) equivalent programs and must never be used during pregnancy.


Export Documentation & Global Supply Compliance


At Ernest Impex, we ensure seamless international customs clearance by providing a comprehensive, audit-ready trade documentation stack with every wholesale shipment:

  • Certificate of Analysis (COA): Providing verifiable batch analysis verifying the exact $10\text{ mg}$ Lenalidomide concentration, active pharmaceutical dissolution profiles, and absolute chemical purity indices.

  • Certificate of Origin (COO): Authenticating true manufacturing provenance within verified, registered Indian production lines.

  • Customs-Compliant Manifesting: Precision shipping manifests, clean packing lists, and commercial invoicing marked with correct global harmonized system (HS) codes for seamless clearance.




📞 Contact Ernest Impex — Pharmaceutical Exporter from India


[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]


🌐 Websites:


📧 Email: exports@ernestpharmaceuticals.com


📦 Business Type: Exporter | Bulk Supplier | Distributor

📲 WhatsApp: +91 93599 02383

📲 WhatsApp Link: https://wa.me/919359902383

 2026-05-18T11:56:01

Keywords